首页> 外国专利> PRODUCTION OF 3-HYDROXY- 3,31-DIHYDROXY- AND 1-DESOXY-1-OXA-RIFAMYCIN S BY RECOMBINANT STRAIN OF NOCARDIA MEDITERRANEI N MEDITERRANEI DSM

PRODUCTION OF 3-HYDROXY- 3,31-DIHYDROXY- AND 1-DESOXY-1-OXA-RIFAMYCIN S BY RECOMBINANT STRAIN OF NOCARDIA MEDITERRANEI N MEDITERRANEI DSM

机译:用诺氏烟草N DS的重组菌株生产3-羟基3,31-二羟基和1-脱氧1-氧杂利福霉素S。

摘要

New antibiotically active compounds having the basic structure of rifamycin S, namely 3-hydroxyrifamycin S (formula A: X=C=O; R1=OH; R2=H), 3,31-dihydroxyrifamycin S (formula A: X=C=O; R1=R2=OH) and 1-desoxy-1-oxarifamycin S (formula A: X=-O-; R1=R2=H) IMAGE (A) are formed by cultivating, under aerobic conditions, a strain of Nocardia mediterranei which is derived from Streptomyces mediterranei ATCC 13 685 as the parent strain and is characterized by the ability to produce at least one of the mentioned compounds. The recombinant strain Nocardia mediterranei DSM 1415 has proved suitable. The mentioned rifamycin S analogues have analogous antibiotic properties to this but have a wider range of action, especially against gram-negative bacteria.
机译:具有利福霉素S基本结构的新型抗生素活性化合物,即3-羟基利福霉素S(分子式A:X => C = O; R1 = OH; R2 = H),3,31-二羟基利福霉素S(分子式A:X => C = O; R 1 = R 2 = OH)和1-脱氧-1-奥沙法霉素S(式A:X = -O-; R 1 = R 2 = H)。(A)通过在有氧条件下培养而形成。衍生自地中海链霉菌ATCC 13 685作为亲本菌株的地中海诺卡氏菌菌株,其特征在于能够产生至少一种上述化合物。重组菌株Nocardia mediterranei DSM 1415已证明是合适的。提到的利福霉素S类似物具有类似的抗生素特性,但是具有更广泛的作用范围,尤其是针对革兰氏阴性细菌。

著录项

  • 公开/公告号NZ192715A

    专利类型

  • 公开/公告日1982-11-23

    原文格式PDF

  • 申请/专利权人 CIBA GEIGY AG;

    申请/专利号NZ19800192715

  • 发明设计人 SCHUPP T;TRAXLER P;NUESCH J;

    申请日1980-01-24

  • 分类号C07D498/08;C07D498/18;C12P17/18;

  • 国家 NZ

  • 入库时间 2022-08-22 11:03:36

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号